News | March 12, 2008

CMS Decides Not to Limit CTA Coverage

March 12, 2008 – The Centers for Medicare & Medicaid Services (CMS) today decided not to move forward with its proposed National Coverage Decision (NCD) that would have limited Medicare coverage of computed tomographic angiography (CTA) to only those instances where CTA is used as part of an ongoing clinical study.

The CMS said, “We have decided that no national coverage determination on the use of cardiac computed tomography angiography for coronary artery disease is appropriate at this time and that coverage should be determined by local contractors through the local coverage determination process or case-by-case adjudication.”

In response, the American College of Cardiology (ACC) publicly applauded CMS’ decision not to move forward with this proposal.

“Medicare beneficiaries can continue to have the access they deserve to an advanced, non-invasive clinical tool that has been clinically proven to be effective in diagnosing coronary Artery disease (CAD),” said ACC CEO Jack Lewin.

Since CMS’s initial proposal to limit CTA coverage in December 2007, the ACC has been working as part of a multi-society effort to oppose the draft decision for the following reasons:

* The NCD would have overruled and replaced Medicare Carrier Local Coverage Decisions (LCDs) made in all fifty states that provide coverage of CTA for indications established as appropriate.
* The decision to only permit CTA Coverage with Evidence Development (CED) would have -paradoxically-hindered the currently robust clinical research surrounding CTA that is already occurring.
* The research used in formulating the NCD appeared to be much older and associated with CTA technologies no longer considered by medical societies as appropriate for use in diagnosing CAD. For example, most of the research cited by CMS focused on CTA machines that provide 4, 8, or 16-slice images, whereas currently 64-slice or better imaging devices are considered the clinical standard for use in diagnosing CAD.
* By limiting Medicare coverage for CTA, CMS would have ignored the substantial amount of clinical evidence supporting the use of CTA in diagnosing CAD

For more information: www.cms.hhs.gov/MCD/viewdecisionmemo.asp?id=206 and www.acc.org

Related Content

iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | Computed Tomography (CT) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Post-Mortem CT Angiography Illuminates Causes of Death
News | CT Angiography (CTA) | June 25, 2018
Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-...
360 Photos | 360 View Photos | June 14, 2018
This is a 360 degree image from the Canon Aquilion 64-slice...
360 Photos | 360 View Photos | May 02, 2018
This is a 360 degree image from the Canon Aquilion One 320-slice computed tomography (CT) system installed at...
iSchemaView Receives FDA Clearance for Rapid CTA
Technology | CT Angiography (CTA) | May 01, 2018
Cerebrovascular imaging analysis company iSchemaView received final clearance from the U.S. Food and Drug...
HeartFlow FFRct Analysis Added to ITP Payment Program in the U.K.
News | CT Angiography (CTA) | April 25, 2018
HeartFlow Inc. announced that the National Health Service (NHS) England has chosen the HeartFlow FFRct (fractional flow...
New Policy Decisions Give Millions Access to HeartFlow FFRct Analysis
News | Cardiac Imaging | February 01, 2018
February 1, 2018 – HeartFlow announced that seven new commercial payers issued positive medical policies covering the
Overlay Init